Malaria infection has been a very serious public health problem in Nigeria and most parts of Africa. Development of antimalarial treatments capable of providing a permanent cure for malaria has been a herculean task for drug researchers. A trial of a novel, proprietary blend formulation (Triantimal TM ) in gel caps for children (n = 112) and water-soluble, 18.51 nm diameter, NutraNanoSphere TM encapsulated Triantimal TM drops for babies (19.9 Months ± 8.7 SD, n = 15) was conducted in Osogbo, Nigeria. The enrolled subjects were screened for malaria, treated with Triantimal TM for 16 consecutive days and sera collected on days 0, 5, 10, 16, 30, 60, and 730. Also, 31 of the children donated buffy coat samples for the gene expression studies when sera were collected. The children showed 90.2% parasite-free at 60 days and 85.1% at 730 days. The babies revealed 93.3% parasite-free at 60 days. These data show for the first time a real possibility for a cure of malaria in Nigeria. The one-time, low dose, extended treatment and synergism of the natural components minimize the ability of the parasites to develop resistance, while boosting the immune system. Indeed, the DNA amplification data showed that all aspects of the humoral, innate, and innate defensin immunity are involved in the long-term immunity against P. falciparum in which may be termed a type of "in vivo immunization".
Introduction
Half of the world's population, over 3.3 billion people are at risk of malaria of which 1.2 billion are at high risk and 97 countries have ongoing malaria transmission. Nowhere is this challenge greater than Africa and specifically in Nigeria. Nigeria has more reported cases of malaria and deaths due to malaria than any other country in the world, where there are estimated 100 million malaria cases with over 300,000 deaths per year due to the most serious type of malaria, Plasmodium falciparum [1] . The virulence of P. falciparum is closely associated with its immune response-evading ability, which is more complicated by the involvement of blood-brain barrier disruption followed by leukocyte infiltration [1] .
Individuals living in malaria endemic areas may become clinically immune after multiple re-infections over time and remain infected without apparent symptoms. However, why a long time period is required to gain clinical immunity to malaria is not clear [1] .
Many diseases, including malaria, tuberculosis, and acquired immune deficiency syndrome (AIDS) have not been good vaccine candidates, and intrinsic barriers may impede approaches limited solely to generating antibodies. In 2017, the result of final clinical trial of the first viable malaria vaccine offers only partial protection against malaria for up to four years. The vaccine is called RTS, S and has been developed over the past 30 years by GlaxoSmithKline Pharmaceuticals and the Bill & Melinda Gates Foundation at an estimated cost exceeding over a half a billion dollars. The RTS, S is designed for children in African countries and is approved by international regulators. However, early trial data from 2011 and 2012-carried out on 16,000 children from seven African countries-showed that vaccines in babies aged 5 -17 months were only effective in 46% of the cases, diminishing hopes that RTS, S will be a viable vaccine [2] .
In this paper, we present a type of "in vivo vaccination" in children and babies that may complement the current vaccine studies with malaria. This research presents the role humoral, cellular, and innate immunity play in our high cure rates with long-term protection against malaria re-infection. Our malaria formulation does not require refrigeration, booster reapplication, and is a one-time treatment regiment for 16 days, which results in long-term immunity over 14 years (Haiti examples) or two years so far in Nigeria.
The objectives of this study include assessment of the antimalarial efficacy of a micellized, water-soluble liquid version for babies and gel caps for children of TriAntiMal TM and are to report the analyses of buffy coat samples during and after treatment for DNA gene expression to determine why patients experience long-term immunity.
Materials and Methods
Study site: The study was conducted at the Primary Health Centre, Sabo area, Committee with monitoring by designated representatives of the HREC committee. One hundred children, ages between 2 and 15 years old, were recruited into the study to determine the overall curative rate of Plasmodium falciparum in the patients. Babies, 9 -36 months old with active malaria, were treated with the water-soluble formulation.
Study design: Patients were screened for fever by using infra red thermometer and those found to have temperatures 37.5˚C -38.4˚C. The axillary temperature of selected patients was further checked to fall within the values stated above before they were referred for a Giemsa-stained thick blood smear. Those with a positive smear results were assessed by study clinicians for the following inclusion criteria:
Patient diagnosed to have malaria with parasitemia load of 2,000 -100,000 parasites/µl; fever with axillary temperature greater or equal to 37.5˚C; age 2 -15 years;
HIV screened negative; those who would be available to have their blood drawn as scheduled; willingness to comply with the daily oral medicine of 16 days.
Patient Exclusion criteria included the following: unwillingness to take the Malaria Formulation for 16 consecutive days; concomitant infection, i.e., malaria infected patient that has any other infection; treatment with any anti-malaria in the next one week before presentation; acute severe complicated malaria e.g.
vomiting frequently that requires the administration of intravenous fluid, convulsion, severe anaemia with PCV < 18%, clinical evidence of pulmonary oedema, feature suggestive of renal failure, history of dark brown color urine which is suggestive of severe red blood cell haemolysis; hyperparasitemia with >10 5 parasites/µl; Patient with temperature > 37.5˚C; hyperpyrexia with temperature ≥ 40˚C; low density Parasitemia: <2 × 10 3 parasite per micro litre; HIV screened positive; and inability to obtain parental consent. All treatments were directly administered at the clinic and patients observed for 30 minutes and doses re-administered when vomiting occurred, but those with repeated vomiting on day 0 were excluded from the study.
Laboratory procedures. Blood smears were air dried, stained with a 2% Giemsa solution for 15 min, rinsed with water and re-air dried and viewed under the microscope using oil immersion lens. Parasite densities were calculated from thick smears as the number of asexual parasites per 200 leukocytes (or per 500 leukocytes if the parasite density was <10 parasites per 200 leukocytes), assuming a leukocyte count of 6 × 10 3 leukocytes/µL. Smear findings were considered negative when microscopic examination of 100 high-power fields did not reveal parasites. Counts were performed by two microscopists and discrepant readings resolved by a third reader. Thin blood smears were performed to evaluate parasite species. Packed cell volume was measured from finger-prick blood samples using heparinised capillary tube. HIV screening tests were done by finger prick sampling using accurate and Determine HIV strips, respectively. Five ml of venous blood were taken, and the buffy coats sera were sent to USA for further investigations by Dr. Thornthwaite To understand the immune processes involved in long-term immunity, serums (n = 112) and buffy coats (n = 31) were from the original children at days 0, 5, 10, 16, 30, 60, and 730. In this paper, data will also be presented with new children (n = 51) and adults (21 were determined and the results of these are shown in Tables 1-6 and Figure 2 and ACTB-most abundant proteins in eukaryotic cells and are involved in cell motility, structure, and integrity. Negative control.
DEFB1-an antimicrobial peptide implicated in the resistance of epithelial surfaces to microbial colonization.
IFNG-an antimicrobial peptide implicated in the resistance of epithelial surfaces to microbial colonization.
IL6-secreted by T cells and macrophages to stimulate immune response during infection and after trauma.
CD160-expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity.
DEFB119-antimicrobial peptide produced by neutrophils that protects tissues and organs from infection by a variety of microorganisms.
IL10-a cytokine synthesis inhibitory factor, which is an anti-inflammatory cytokine.
LAG3-inhibitory receptor expressed on activated CD8 and CD4 T cells (including Tregs) triggering signalling within Dendritic cells.
CD19-expressed during all phases of B cell development until terminal differentiation into plasma cells.
DEFB127-Defensins are cysteine-rich cationic polypeptides that are important in the immunologic response to invading microorganisms.
IL12A-acts on T and natural killer cells and has a broad array of biological activities.
NFKB1-involved in the regulation of genes that impact not only immune responses but also cell proliferation, survival, and differentiation.
CD4-co-receptor of the T cell receptor (TCR) and assists the latter in communicating with antigen-presenting cells.
EGF-Epidermal growth factor is a growth factor that stimulates cell growth, proliferation, and differentiation by its receptor EGFR.
IL12B-expressed by activated macrophages, essential inducer of Th1 cells development for protection to intracellar pathogens.
PDCD1-Programmed Cell Death Protein 1, part of the immunoglobulin superfamily and is expressed on T cells and pro-B cells.
CD40-expressed on activated T cells, part of the TNF superfamily of molecules on antigen-presenting cells (APC).
GAPDH-Glyceraldehyde 3-phosphate dehydrogenase catalase the sixth step of glycolysis, initiation of apoptosis, ER to Golgi shuttling.
IL18-proinflammatory cytokine that belongs to the IL-1 superfamily, produced by macrophages and other cells.
TGFA-TGF-α can be produced in macrophages, brain cells, and keratinocytes. TGF-α induces epithelial development.
CD8A-found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system.
HBD-Haemoglobin subunit delta is a protein that in humans. Negative control.
IL2-promotes the differentiation of T cells into effector T cells and into memory T cells helping the body fight off infections.
CD8B-found on most cytotoxic T lymphocytes that mediates efficient cell-cell interactions within the immune system.
IFNA1-produced by macrophages and has antiviral activity.
IL4-cytokine that induces differentiation of naive helper T cells (Th0 cells) to Th2 cells.
DEFA1-antimicrobial and cytotoxic peptides thought to be involved in host defense.
IFNB1-antiviral, antibacterial, and anticancer properties.
IL5-cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. Table 2 shows the 29 primer designs used to detect gene expression levels.
The choice of these primer markers was based on a survey of possible markers associated with malaria infection. 
Results

Malaria Parasite Load (MPL) during and after Treatment for Babies and Children
The P. falciparum Malaria Parasite Load (MPL) clearance curve with standard deviation (SD) bars included the original children and the buffy coat children of the P. falciparum-free children is shown in Figure 2 . In the combined children study (n = 121), the ages ranged between 2.5 and 15 years old for an average age of 8.4 ± 3.6 SD (n = 110) for the cured children and 8.3 ± 2.4 (n = 11) for the recurrent children. The average MPL at day zero was about 22,000 for both the cured and recurrent patients. The patient groups were almost equally divided (Males 52.8 ± 5.8 SD n = 121) between males and females. The cure rate in the Original Children's study was 90.2% and decreased 5.1% by Day 730 (n = 51). Figure 3 is a graphic representation of Table 1 showing the rapid clearance of the P. falciparum in babies with 93.3% parasite-free at 60 days. Table 2 shows the DNA markers used in this initial study. These markers were chosen because of their possible association with malaria. These DNA amplification markers were grouped into Interleukins, Cytokines, Interferons, Defensins, and various markers for inflammation. The term "neutral" used throughout refers to a value not changing from the Day 0 values of each of the DNA markers.
The DNA Markers
The DNA marker term "negative" means the DNA was down regulated. The DNA marker term "positive" means the DNA was up regulated. All DNA marker values were standardized to their respective Day 0 values.
Children Days 0 -730
In Table 3 Table   3 describes some the more notable changes during and after treatment.
A summary Table 4 of the DNA markers from Table 3 for the children cen- Table 5 presents the mean DNA marker results from 14 buffy coat samples, obtained from cured babies as described in the Materials and Methods section.
Babies Days 0 -60
Buffy coats and sera were obtained from babies at days 0, 16, 30, and 60 during and after the 16-day treatment. Instead of gel caps, the babies were given the water-soluble NutraNanoSpheres TM , 7 -10 nm diameter micellized drops directly into their milk bottles daily. In Table 6 is a summary of the DNA markers from Table 2 Table 7 shows the comparisons between the DNA amplification markers be- and remained negative or neutral throughout. The babies were neutral for these markers, except for the positive NFKB1. The children showed positive CD8B, CD19. IL2, IL4, IL12B, LAG3, and INFB1 (neutral to positive) after a negative Day 5. In contrast, the babies did not show the negative to positive transition for these markers. The babies, however, did reveal positive to negative reduction for the DNA makers CD8B, CD19, IL5, and GAPDH. In contrast, the children did not show the positive to negative transition for these markers.
Summary of DNA Amplification Markers: Children vs. Baby Comparisons
Discussion
IL12A and Il12B. Life-threatening complications in severe childhood malaria include hyperparasitemia, hypoglycemia, cerebral malaria, respiratory distress, and severe malaria anemia [3] [4] . There are strong associations between polymorphisms in the genes of IL12A and IL12RB1 and protection from SMA in Kenyan children, suggesting that human genetic variants of IL12 related genes may significantly contribute to the development of anemia in malaria patients [5] . Treatment with IL12 corrects malarial anemia [6] [7] [8] . In the children (Table 3 and summary Table 4 ) and in the babies during treatment (Table 5  and summary Table 6 ), gene amplification of IL12A and IL12B were significantly positive. Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. The elevation of both EGF and IL12 (summary Table 4 and Table 6 ) in the children and babies has a positive prognostic significance [9] .
For the other Interleukins in children, IL2, IL4, and IL12B were negative at Day 5 and were positive by Day 10 and beyond relative to Day 0. IL6 was negative (downregulated) at Day 5 and subsequently became neutral (expression remained unchanged). IL2 is important for the proliferation of T and B lymphocytes, especially among young children. The receptor for this cytokine is a heterotrimeric protein complex whose gamma chain is also shared by Interleukin 4 (IL4) and Interleukin 7 (IL7) [10] . IFN-gamma levels were elevated in patients with complicated malaria in the initial stage of the disease before treatment compared to the levels found with uncomplicated malaria, while the IL4 levels were elevated 7 days after treatment [11] .
through several distinct roles in T cell activation and T cell interaction with other immune cells. In a mouse model of immunity to liver stage plasmodial infection, CD40 had been shown to be critical for the full maturation of liver dendritic cells, accumulation of CD8(+) T cells in the liver, and protective immunity [19] .
In studies like reported here, Glucose-6-phosphate dehydrogenase (GAPDH) is usually used as an internal marker for monitoring gene expression or in some situations used to normalize the gene expression levels. We use the values at Day zero to normalize our data. However, GAPDH is important in the control of oxidant stress in erythrocytes, the host cells for P. falciparum. Mutations in this enzyme produce X-linked deficiency states associated with protection against malaria, notably in Africa where the A form of GAPDH deficiency is widespread [20] . In the children, GAPDH was positive throughout, while the babies were positive at Day 16 and then became negative by Day 30. Therefore, it appears a GAPDH deficiency
In Table 7 , the comparisons between the children and the babies' immunologic genes expression showed many similarities with some exceptions. At the Table 7 . There were at least six more genes that were negative for the children when compared to the babies.
One of the most interesting results was the upregulation of the defensins genes in both the children and babies. In the children, while DEFB1 and DEF127 remained neutral (unchanged), significantly upregulated (statistical test, p value) were measured for DEFA1 and DEFB119, even at Day 730 in the cured children. The babies uniquely showed upregulation for DEF127 and DEFA1, as also for the children, at Day 16, which downregulation occurred through Day 60. DEFB1 was unchanged in the babies. To these authors knowledge, there have not been any papers published on Defensins AND Malaria (PubMed.com). Furthermore, the innate activity of defensins has been thought to be restricted to antiviral and antibacterial activity. The mechanism(s) of how they would operate against parasites internally is not clear. Based on the intracellular destruction of bacteria in neutrophils containing defensin granules, there may be the possibility that defensins can operate within the liver and erythrocytes infected with the parasites. Furthermore, the significant upregulation (p value) of the immune regulatory genes, e.g. DEFA1 in children at Day-16 through day-730, may be showing immunological memory among defensins against P. falciparum.
The unique, common biochemical structure of defensins contains six cyste-J. T. Thornthwaite ing from bony fish to human [24] and are found in plants [25] .
DEFA1 genes encode human neutrophil peptides (HNP) 1 -3 and are involved in directly killing pathogens [26] [27]. HNP1-3 also is functionally associated with innate immunity and infections [28] [29].
Beta-defensins, such as DEFB1, DEFB119, and DEFB127 presented here, are antimicrobial peptides that protect tissues and organs from infection by a variety of microorganisms like the DEFA1 Alpha Defensins described above [30] [31]
[32] [33] . A specific β-defensin called tracheal antimicrobial peptide (TAP) is found along the entire length of conducting airways [34] . In the lung, the β-1 with HIV-1 [38] . However, there is no evidence from the literature that defensins protect against malaria parasites and show immunological memory. We may be reporting for the first time process that accentuates the production of defensins, which may have immunological memory due to the upregulation of specific immune regulation genes long after parasite clearance in children (Table   3 ).
Conclusions
We present a result of chemotherapy that seems to enhance the immunity of in- antibodies and antibody types against P. falciparum which appear in the bloodstream during the steps to immunity and see how they correlate with the DNA activation data in this paper.
Finally, we need to address the whole process of how we cure malaria. Waiting for the parasite to be manifested in the blood before treatment begins may not be the correct way to treat malaria. Our treatment is safe and efficacious, may justify treating individuals indigenous to a malaria infested country, since liver and other organs may harbor the P. falciparum. Regardless, if we are going to make a major impact on ridding the world of this devastating disease, we must be willing to focus on a treatment that is curative, one-series treatment, safe, and inexpensive. This research also introduces the hope of curing bacterial and viral diseases, cancer and other life-threatening diseases.
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